186Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents: Comparison of physical and biological characteristics with 125I and 131I-labeled counterparts

Cancer Biotherapy and Radiopharmaceuticals

Volumn 11, Issue 2, 1996, Pages 133-144

  Kotts, C E ^a   Su, F M ^b   Leddy, C ^a   Dodd, T ^b   Scates, S ^c   Shalaby, M R ^a   Wirth, C M ^a   Giltinan, D ^a   Schroff, R W ^b   Fritzberg, A R ^b   Shepard, H M ^d   Slamon, D J ^c   Hutchins, B M ^d  

^a GENENTECH INC   (United States)

^b Poniard Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE; RADIOISOTOPE; RHENIUM; ANTIBODY; IODINE 125; IODINE 131; RADIOPHARMACEUTICAL AGENT; RHENIUM 186;

ANIMAL; ARTICLE; CELL STRAIN U937; CHEMISTRY; COMPARATIVE STUDY; HUMAN; IMMUNOLOGY; ISOTOPE LABELING; MOUSE; RADIOIMMUNOTHERAPY; ANTIBODY LABELING; ANTIGEN EXPRESSION; GENE EXPRESSION; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL; PROTO ONCOGENE;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IODINE RADIOISOTOPES; ISOTOPE LABELING; MICE; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RECEPTOR, ERBB-2; RHENIUM; U937 CELLS;

EID: 0029657591     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1996.11.133     Document Type: Review

References (43)

1. Coussens L, Yang-Feng LT, Liao Y-C, Chen E, Gray A. McGrath J, Seeburg PH, Liebermann TW, Schlessinger J, Franke U. Levinson A, and Ullrich A Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (Wash. DC) 1985;230:1132.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene Science (Wash. DC) 1987;235:177.
3. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A and Press MF. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science (Wash. DC) 1989;244:707.
4. Park JB, Rhim JS, Park SC, Kimm SW and Kraus MH. Amplification, overexpression, and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomas. Cancer Res 1989;49:6605.
5. Tsujino T, Yoshida K, Nakayama H, Ito H, Shimosato T and Tahara E. Alterations of oncogenes in metastatic tumors of human gastric carcinomas. Br J Cancer 1990;62:226.
6. neu) in human non-small cell carcinomas of the lung. Cancer Res 1990,50:421.
7. Zhau HE, Zhang S, von Eschenbach AC, Scorsone K, Babaian RJ, Ro JY and Hung MC. Amplification and expression of the c-erb B-2/neu protooncogene in human bladder cancer. Mol Carcinogen 1990; 3:254.
8. Hall PA, Hughes CM, Staddon SL, Richman PI, Gullick WJ and Lemoine NR. The c-erbB-2 protooncogene in human pancreatic cancer. J Pathol 1990;161:195.
9. Berchuk AB, Rodriguez G, Kinney RB, Soper JT, Dodge RK, Clarke-Pearson DL and Bast RO. Overexpression of HER2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 1991,164:15.
10. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM and Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989;9:1165.
11. Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA and Ullrich A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990;50:1550.
12. Shepard HM, Lewis GD, Samp JC, Fendly BM, Maneval D, Mordenti J, Figan I, Kotts CE, Palladino MA. Ullrich A and Slamon D. Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic. J Clin Immunol 1991;11:117.
13. HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992;89:4285.
14. DeSantes K, Slamon D, Anderson SK, Shepard M, Fendly B, Maneval D and Press O. Radiolabeled antibody targeting of the HER2/neu oncoprotein. Cancer Res 1992;52:1916.
15. 186Re radioimmunotherapy of small cell lung carcinoma xenografts. Cancer Res 1991;51:676.
16. Kraus CR, Popescu NC, Amsbaugh SC and King CR. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 1987;6:605.
17. Munson PJ and Rodbard D. LIGAND: A versatile computerized approach for characterization of ligand-binding systems Anal Biochem 1980,107.202.
18. Harwerth I-M, Wels W, Marte Band Hynes NE. Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. J Biol Chem 1992;267:15160
19. Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, and Shawver LK. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diammine dichloroplatinum against human breast and ovarian tumor cell lines Cancer Res 1991;51 4575.
20. Styles JM, Harrison S, Gutterson BA and Dean CJ. Rat monoclonal antibodies to the external domain of the product of the C-erbB-2 proto-oncogene. Int J Cancer 1990;45:320
21. McKenzie SJ, Marks PJ, Lam T, Morgan J, Panicali DL, Trimpe KL and Carney WP. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene 1989,4:543.
22. Centis F, Tagliabue E, Uppugundun S, Pellegrini R, Martignone S, Mastroianni A, Menard S and Colnoghi MI. p185 HER2/neu epitope mapping with murine monoclonal antibodies. Hybridoma 1992,11:267.
23. HER2. Hybridoma 1992.11:519.
24. Drebin JA, Stem DF, Link VC, Weinberg RA, and Greene MI. Monoclonal antibodies identify a cell surface antigen associated with an activated cellular oncogene Nature 1984;312:545.
25. Drebin JA, Link VC, Stem DF, Weinberg RA and Greene MI. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 1985;41:695
26. Harwerth JM, Wels W, Schlegel J, Muller M and Hynes NE Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br J Cancer 1993;68:1140.
27. Kasprzyk PG, Song SU, DiFiore PP and King CR. Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res 1992;52:2771
28. Maier LA, Xu FJ, Hester S, Boyer CM, McKenzie S, Bruskin AM, Argon Y and Bast RC. Requirements for the internalization of a murine monoclonal antibody directed against the HER2/neu gene product c-erbB-2. Cancer Res 1991;51:5361.
29. Drebin JA, Link VC, Weinberg RA and Greene MI. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen Proc Natl Acad Sci USA 1986;83:9129.
30. Drebin JA, Link VC, and Greene MI. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 1988;2:387
31. Tec ce R, Digiesi G, Savarese A, Trizio D and Natali PG Characterization of cytotoxic activity of saporin anti-GP185/HER2 immunotoxins. Int J Cancer 1993;55:122.
32. DeNardo SJ, Warhoe KA, O'Grady LF, Hellstrom I, Hellstrom KE, Mills SL, Macey DJ, Goodnight JE, and DeNardo GL. Radioimmunotherapy for breast cancer: Treatment of a patient with I-131 L6 chimeric monoclonal antibody. Int J Biol Markers 1991;6:221.
33. Order SE, Stillwagon GB, Klein JL, Leichner PK, Siegelman SS, Fishman EK, Ettinger DS, Haulk T, Kopher K, Finney K, Surdyke M, Self S and Leibel S Iodine 131 antiferritin, a new treatment modality in hepatoma: a radiation therapy oncology group study J Clin Oncol. 1985;3:1573.
34. Zeng ZC, Tang ZY, Xie H, Liu KD, Lu JZ, Chai XJ, Wang GF, Yao Z and Qian JM. Radioimmunotherapy for unresectable hepatocellular carcinoma using 131-I-hapama-1 mAb preliminary results. J Cancer Res Clin Oncol 1993;119:257.
35. Bernstein ID: Eary JF, Badger CC, Press OW, Appelbaum FR, Martin PJ, Krohn KA, Nelp WB, Porter B, Fisher D, Miller R, Brown S, Levy R, and Thomas ED. High dose radiolabeled antibody therapy of lymphoma. Cancer Res (Suppl) 1990;50:1017s.
36. 131I] anti-B1 (anti-CD20) antibody. New Engl J Med 1993;329:459.
37. Press OW, Eary JF, Applebaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B, Matthews DC, Fisher LD and Bernstein ID. Radiolabeled-antibody therapy of a B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219.
38. Breitz HB, Weiden PL, Vanderheyden JL, Appelbaum JW, Bjorn MJ, Fer MF, Wolf SB, Ratcliff BA, Seiler CA, Foisie DC, Fisher DR, Schroff RW, Fritzberg AR and Abrams PG. Clinical experience with rhenium 186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials. J Nucl Med 1992;33:1099
39. Jacobs AJ, Fer M, Su FM, Breitz H, Thompson J, Goodgold H, Cain J, Heaps J, and Weiden P. A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response. Obstet Gynecol 1993;82:586.
40. Nikula TK, Bocchia M, Curcio MJ, Sgouros G, Yan M, Finn RD, and Scheinberg DA Impact of the high tyrosine fraction in complementarity determining regions: Measured and predicted effects of radioiodination on IgG immunoreactivity. Mol Immunol 1995;12:865.
41. 131I-labeled antibody in multicell spheroids. Int J Radiation Oncol Biol Phys 1992;24:127.
42. John E, Thakur ML, DeFulvio J, McDevitt MR and Damjanov I. Rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: preparation and evaluation. J Nucl Med 1993;34:260.
43. 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor Cancer Res 1992;52:121.